RE

Renovaro IncNASDAQ RENB Stock Report

Last reporting period 31 Mar, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.097

Micro

Exchange

XNAS - Nasdaq

RENB Stock Analysis

RE

Uncovered

Renovaro Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.097

Dividend yield

Shares outstanding

147.5 B

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The firm has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

View Section: Eyestock Rating